Akers Biosciences Inc (NASDAQ:AKER) has announced entering into a three-year national distribution agreement with Diagnostica Stago Inc for its flagship product.

Under the agreement, which will be in effect for three years, Stago will supply South Akers PIFA PLUSS PF4 Rapid Assay, which is based in jersey with a single-use test for Heparin-induced thrombocytopenia to hospital laboratories in the whole of United States.

Thrombocytopenia (HIT) induced with Heparin is a clinical symptom which reverses the blood-thinning therapeutic effect of heparin and instead and makes it a clotting agent. HIT patients always have a reduced number of platelet in blood and are at a high risk of developing limb as well as life-threatening complications.

Every year, around 4 million tests of HIT are carried out in the United States. According to Akers, these tests offers much faster results compared to the conventional methods used to detect HIT.  The PIFA PLUSS PF4 uses a blood sample to quickly detect platelet factor 4 antibodies. It is made in such a way that it detects in less than one hour.

The terms of the agreement are yet to be revealed. While commenting on the agreement, Akers Bio CEO John J. Gormally said by including Stago to Akers’ distribution channels, the company will have attained an important step in the commercialization of PIFA PLUSS PF4.  He added that Stago will enable Akers to gain a lot of access to specialized and dedicated sales team and who are focused on buyers of hemostasis-related drugs.

Stago is a French based company and specializes in production of medical products and also has operations on U.S. It is engaged in the sale and support of hemostasis equipment and products to U.S hospitals.

THE MORNING REPORT

Start your workday the right way with the news that matters most.

Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy

Stago North America CEO Philippe Barroux said his company will be in charge of marketing the PIFA PLUSS PF4 Rapid Assay as the only fast test for the heparin platelet factor 4 antibodies in the whole of U.S. he added that test has a lot of economic and medical benefits.

Started in 1989, Akers Bio which is based in Thorofare, Gloucester County, specializes in the development, manufacture, and distribution of rapid screening and testing products meant to offer fast and affordable health care information to consumers and providers.